591 related articles for article (PubMed ID: 12021250)
1. Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy.
Petersen KF; Oral EA; Dufour S; Befroy D; Ariyan C; Yu C; Cline GW; DePaoli AM; Taylor SI; Gorden P; Shulman GI
J Clin Invest; 2002 May; 109(10):1345-50. PubMed ID: 12021250
[TBL] [Abstract][Full Text] [Related]
2. [Therapy resistant diabetes mellitus and lipodystrophy: leptin therapy leads to improvement].
Jazet IM; Jonker JT; Wijngaarden MA; Lamb H; Smelt AH
Ned Tijdschr Geneeskd; 2013; 157(4):A5482. PubMed ID: 23343738
[TBL] [Abstract][Full Text] [Related]
3. The liver diseases of lipodystrophy: the long-term effect of leptin treatment.
Safar Zadeh E; Lungu AO; Cochran EK; Brown RJ; Ghany MG; Heller T; Kleiner DE; Gorden P
J Hepatol; 2013 Jul; 59(1):131-7. PubMed ID: 23439261
[TBL] [Abstract][Full Text] [Related]
4. Leptin ameliorates insulin resistance and hepatic steatosis in Agpat2-/- lipodystrophic mice independent of hepatocyte leptin receptors.
Cortés VA; Cautivo KM; Rong S; Garg A; Horton JD; Agarwal AK
J Lipid Res; 2014 Feb; 55(2):276-88. PubMed ID: 24293639
[TBL] [Abstract][Full Text] [Related]
5. Treatment of diet-induced lipodystrophic C57BL/6J mice with long-acting PASylated leptin normalises insulin sensitivity and hepatic steatosis by promoting lipid utilisation.
Bolze F; Bast A; Mocek S; Morath V; Yuan D; Rink N; Schlapschy M; Zimmermann A; Heikenwalder M; Skerra A; Klingenspor M
Diabetologia; 2016 Sep; 59(9):2005-12. PubMed ID: 27272237
[TBL] [Abstract][Full Text] [Related]
6. Leptin activates hepatic 5'-AMP-activated protein kinase through sympathetic nervous system and α1-adrenergic receptor: a potential mechanism for improvement of fatty liver in lipodystrophy by leptin.
Miyamoto L; Ebihara K; Kusakabe T; Aotani D; Yamamoto-Kataoka S; Sakai T; Aizawa-Abe M; Yamamoto Y; Fujikura J; Hayashi T; Hosoda K; Nakao K
J Biol Chem; 2012 Nov; 287(48):40441-7. PubMed ID: 23024365
[TBL] [Abstract][Full Text] [Related]
7. Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy.
Javor ED; Ghany MG; Cochran EK; Oral EA; DePaoli AM; Premkumar A; Kleiner DE; Gorden P
Hepatology; 2005 Apr; 41(4):753-60. PubMed ID: 15791619
[TBL] [Abstract][Full Text] [Related]
8. Leptin-replacement therapy for lipodystrophy.
Oral EA; Simha V; Ruiz E; Andewelt A; Premkumar A; Snell P; Wagner AJ; DePaoli AM; Reitman ML; Taylor SI; Gorden P; Garg A
N Engl J Med; 2002 Feb; 346(8):570-8. PubMed ID: 11856796
[TBL] [Abstract][Full Text] [Related]
9. A controlled-release mitochondrial protonophore reverses hypertriglyceridemia, nonalcoholic steatohepatitis, and diabetes in lipodystrophic mice.
Abulizi A; Perry RJ; Camporez JPG; Jurczak MJ; Petersen KF; Aspichueta P; Shulman GI
FASEB J; 2017 Jul; 31(7):2916-2924. PubMed ID: 28330852
[TBL] [Abstract][Full Text] [Related]
10. Leptin decreases de novo lipogenesis in patients with lipodystrophy.
Baykal AP; Parks EJ; Shamburek R; Syed-Abdul MM; Chacko S; Cochran E; Startzell M; Gharib AM; Ouwerkerk R; Abd-Elmoniem KZ; Walter PJ; Walter M; Muniyappa R; Chung ST; Brown RJ
JCI Insight; 2020 Jul; 5(14):. PubMed ID: 32573497
[TBL] [Abstract][Full Text] [Related]
11. Recent advances in understanding lipodystrophy: a focus on lipodystrophy-associated cardiovascular disease and potential effects of leptin therapy on cardiovascular function.
Bruder-Nascimento T; Kress TC; Belin de Chantemele EJ
F1000Res; 2019; 8():. PubMed ID: 31656583
[TBL] [Abstract][Full Text] [Related]
12. Site and mechanism of leptin action in a rodent form of congenital lipodystrophy.
Asilmaz E; Cohen P; Miyazaki M; Dobrzyn P; Ueki K; Fayzikhodjaeva G; Soukas AA; Kahn CR; Ntambi JM; Socci ND; Friedman JM
J Clin Invest; 2004 Feb; 113(3):414-24. PubMed ID: 14755338
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of leptin-replacement therapy and possible mechanisms of leptin actions in patients with generalized lipodystrophy.
Ebihara K; Kusakabe T; Hirata M; Masuzaki H; Miyanaga F; Kobayashi N; Tanaka T; Chusho H; Miyazawa T; Hayashi T; Hosoda K; Ogawa Y; DePaoli AM; Fukushima M; Nakao K
J Clin Endocrinol Metab; 2007 Feb; 92(2):532-41. PubMed ID: 17118991
[TBL] [Abstract][Full Text] [Related]
14. Insulin resistance, acanthosis nigricans, and hypertriglyceridemia.
Eberting CL; Javor E; Gorden P; Turner ML; Cowen EW
J Am Acad Dermatol; 2005 Feb; 52(2):341-4. PubMed ID: 15692481
[No Abstract] [Full Text] [Related]
15. The clinical efficacy of the adipocyte-derived hormone leptin in metabolic dysfunction.
Gorden P; Park JY
Arch Physiol Biochem; 2006 Apr; 112(2):114-8. PubMed ID: 16931453
[TBL] [Abstract][Full Text] [Related]
16. Type 1 diabetes associated with acquired generalized lipodystrophy and insulin resistance: the effect of long-term leptin therapy.
Park JY; Chong AY; Cochran EK; Kleiner DE; Haller MJ; Schatz DA; Gorden P
J Clin Endocrinol Metab; 2008 Jan; 93(1):26-31. PubMed ID: 17940115
[TBL] [Abstract][Full Text] [Related]
17. Metreleptin-mediated improvements in insulin sensitivity are independent of food intake in humans with lipodystrophy.
Brown RJ; Valencia A; Startzell M; Cochran E; Walter PJ; Garraffo HM; Cai H; Gharib AM; Ouwerkerk R; Courville AB; Bernstein S; Brychta RJ; Chen KY; Walter M; Auh S; Gorden P
J Clin Invest; 2018 Aug; 128(8):3504-3516. PubMed ID: 29723161
[TBL] [Abstract][Full Text] [Related]
18. Leptin replacement therapy for the treatment of non-HAART associated lipodystrophy syndromes: a meta-analysis into the effects of leptin on metabolic and hepatic endpoints.
Rodríguez AJ; Neeman T; Giles AG; Mastronardi CA; Paz Filho G
Arq Bras Endocrinol Metabol; 2014 Nov; 58(8):783-97. PubMed ID: 25465598
[TBL] [Abstract][Full Text] [Related]
19. Acquired partial lipodystrophy is associated with increased risk for developing metabolic abnormalities.
Akinci B; Koseoglu FD; Onay H; Yavuz S; Altay C; Simsir IY; Ozisik S; Demir L; Korkut M; Yilmaz N; Ozen S; Akinci G; Atik T; Calan M; Secil M; Comlekci A; Demir T
Metabolism; 2015 Sep; 64(9):1086-95. PubMed ID: 26139569
[TBL] [Abstract][Full Text] [Related]
20. Lipodystrophies-Disorders of the Fatty Tissue.
Knebel B; Müller-Wieland D; Kotzka J
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33233602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
